New cancer clinical trial: Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Published on: July 31, 2018 at 12:00PM
Conditions:   Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy;   MSI-H Tumors
Interventions:   Drug: Nivolumab;   Drug: Relatlimab
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Bristol-Myers Squibb
Not yet recruiting
https://ift.tt/2OzlQZz